Peritoneal Stem Cell Delivery for Stroke Brain Perfusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for stroke, particularly beyond the 4-minute window, are inadequate in protecting against stroke damage, and the use of stem cells for therapeutic purposes is complicated by safety concerns associated with intravenous injection.
Innovation Solution
The method involves delivering stem cells, specifically human placenta mesenchymal stem cells (hPMSCs), into the peritoneum of a patient, either before, during, or after the administration of a clot-busting compound like tissue plasminogen activator (tPA). The stem cells are cultured with cholesterol to increase the number of extracellular vesicles, which are then used to enhance therapeutic recovery from stroke-related tissue damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous stem cell injection is used for stroke treatment, then therapeutic protection against stroke damage is achieved, but safety hazards including fatal complications occur
Solution Approach 1:
The patent introduces the peritoneum as an intermediary compartment between the bloodstream and the brain. Stem cells are injected into the peritoneal cavity rather than directly into the bloodstream, allowing them to serve as a protective intermediary that releases therapeutic factors (exosomes, microparticles) without causing the harmful intravascular effects associated with direct IV injection. This mediator approach maintains therapeutic protection while eliminating fatal safety hazards.
Solution Approach 2:
The patent segments the delivery system by separating the stem cell administration route from the therapeutic action site. Instead of direct intravenous injection, the system uses peritoneal injection as a separate compartment, allowing controlled release of therapeutic factors through exosome/microparticle formation and ACE2 maintenance of brain perfusion, thereby achieving therapeutic protection with improved safety.
2Reliability
If stem cells are delivered intravenously for stroke treatment, then brain protection is achieved, but the treatment window is limited and safety risks increase
Solution Approach 1:
The patent applies preliminary action by pre-positioning stem cells in the peritoneal cavity before stroke onset or at extended time points after stroke initiation. The peritoneal stem cells can be administered before the traditional 4-minute IV window, maintaining protective effects throughout the extended period through continuous exosome/microparticle release and ACE2-mediated perfusion maintenance, thereby eliminating the strict time window limitation.
Solution Approach 2:
The peritoneal stem cell system provides continuous therapeutic action through sustained exosome and microparticle release, as well as ongoing ACE2 maintenance of brain perfusion. This continuous useful action extends the effective treatment window beyond the traditional 4-minute IV limitation, maintaining brain protection over extended periods without the safety risks of intravenous administration.
3Reliability
If stem cells are cultured with cholesterol to increase extracellular vesicles, then therapeutic efficacy is enhanced, but cell culture complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the cell culture environment with cholesterol supplementation to enhance extracellular vesicle production. This parameter modification (adding cholesterol to the culture medium) directly increases the number of exosomes and microparticles released by stem cells, thereby enhancing therapeutic efficacy for stroke protection through ACE2 maintenance and brain perfusion improvement.
Data Source
AI summary
Therapeutics and methods of treating a stroke in a patient comprising delivering stem cells into a peritoneum of the patent. According to a further embodiment the stem cells are mesenchymal stem cells. According to a further embodiment the stem cells are human placenta mesenchymal stem cells (hPMSC). According to a further embodiment the stroke is one of stroke is one of occlusive, post-occlusive, hemorrhagic, and transient ischemic injury. According to a further embodiment the method further comprises the step of delivering a clot busting compound into a blood stream of the patient.